| Are pharmacokinetic equivalence and similar efficacy, safety, and immunogenicity maintained in patients with chronic plaque psoriasis who switched multiple times between adalimumab reference product (RP) and BI 695501? |
| Switching three separate times between adalimumab RP and BI 695501 resulted in pharmacokinetic equivalence, highly similar efficacy and immunogenicity outcomes, and comparable safety compared with patients on continuous adalimumab RP. |
| These findings support the interchangeability of BI 695501 with adalimumab RP. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.